Dr Mark R. Litzow, from the Mayo Clinic, highlights four important acute lymphoblastic leukemia (ALL) studies presented at this year's American Society of Hematology annual meeting.
First, Dr Litzow covers two trials that tested the viability of pediatric-inspired regimens in adult patients with ALL. GRAALL-2005, he explains, is the first trial to evaluate the prognostic impact of central nervous system (CNS) involvement in adults with ALL using a pediatric protocol. He then discusses GMALL-08/2013, a risk-adapted and minimal residual disease (MRD)-stratified trial of patients with newly diagnosed ALL or lymphoblastic lymphoma. GMALL confirmed that a pediatric-intensive regimen shows promising benefits for older adults when used in combination with targeted therapy and stem cell transplantation.
Next, Dr Litzow presents the first promising results from the EWALL-INO study of older patients with CD22+ Philadelphia chromosome–negative B-cell precursor (Ph+) ALL. This phase 2 multicenter study found the safety and efficacy of a combination therapy of reduced fractionated inotuzumab dosing and low-intensity chemotherapy to be an active and well-tolerated frontline therapy.
Finally, he reports on 2298, a late-breaking abstract of updated trial results that may offer an effective transplant-sparing regimen for adult patients with newly diagnosed, relapsed/refractory, or chronic myeloid leukemia Ph+ ALL.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Highlights in Acute Lymphoblastic Leukemia From ASH 2021 - Medscape - Jan 10, 2022.
Comments